Rock2:ER GFP Vector
Invented by Prof Michael Olson at Cancer Research UK Glasgow: The Beatson Institute
- Datasheet
- References (4)
- Inventor Info
Info
Catalogue Number | 152723 |
Backbone Size (bp) | 5169 |
Bacterial Resistance | Ampicillin |
Vector Type | pBabe-puro |
Antigen/Gene or Protein Targets | Rock2, RockII |
Relevance | Rock2:ER Plasmid contains the catalytic domain of human Rock-II fused at the carboxy-terminal end to a mutated ligand binding domain of the estrogen receptor (ER) and also to enhanced green fluorescence protein at the amino terminus. When expressed the Rock2:ER fusion protein is inactive because of the binding of a heat shock protein (HSP90) to the ER ligand binding domain. Addition of the estrogen homolog, 4-hydroxytamoxifen (4-HT), results in displacement of HSP90 and activation of the kinase. |
Research Area | Cancer, Cell Signaling & Signal Transduction, Cell Structure and Motility |
References: 4 entries
Croft et al. 2004. Cancer Res. 64(24):8994-9001. PMID: 15604264.
Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis.
Europe PMC ID: 15604264
McMullan et al. 2003. Curr Biol. 13(24):2185-9. PMID: 14680635.
Keratinocyte differentiation is regulated by the Rho and ROCK signaling pathway.
Europe PMC ID: 14680635
Add a reference
References: 4 entries
Croft et al. 2004. Cancer Res. 64(24):8994-9001. PMID: 15604264.
Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis.
McMullan et al. 2003. Curr Biol. 13(24):2185-9. PMID: 14680635.
Keratinocyte differentiation is regulated by the Rho and ROCK signaling pathway.
Add a reference